财联社7月3日电， 礼来 (LLY.N)的Kisunlam（Donanemab-Azbt）获美国食品药品监督管理局（FDA）批准用于治疗 阿尔茨海默 症。Kisunlam每支售价695.65美元，第一年的费用为3.2万美元，6个月费用为12522美元。
礼来(LLY.N)的Kisunlam（Donanemab-Azbt）获美国食品药品监督管理局（FDA
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.